Khondrion
Philips van Leydenlaan 15 (west entrance)
M357.00.132
Internal route number 427
Nijmegen
6525 EX
Netherlands
Tel: 31-24-361-06-39
Fax: 31-24-361-75-05
Website: http://www.khondrion.com/
Email: info@khondrion.com
About Khondrion
Khondrion was founded by Prof. Dr. Jan Smeitink, a world-leader in mitochondrial medicine. He has devoted his entire career to the care of mitochondrial disease patients, to better understand the complexity of this disease and his life mission is to develop a treatment for these high impacts, often early fatal group of disorders. Fully operational since 2012 and located in Nijmegen, The Netherlands, Khondrion primarily focuses on the development of innovative therapies for inherited mitochondrial diseases, including Leigh Disease, MELAS, Leber’s Hereditary Optic Neuropathy and other Respiratory Chain / Oxidative Phosphorylation disorders.
YEAR FOUNDED:
2012
LEADERSHIP:
Founder and CEO: Jan Smeitink
8 articles about Khondrion
-
The approval of Reata Pharmaceuticals’ Skyclarys for Friedreich’s ataxia highlights progress being made in the treatment of rare mitochondrial diseases.
-
Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders
11/22/2022
Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today provides an update from (A) the 28-day double-blind, randomised, placebo-controlled, three-way cross-over KHENERGYZE Phase IIb study in 27 patients, and (B) the ongoing, open label extension KHENEREXT Phase IIb study (7 patients up to 52 weeks) (both studies jointly the “Phase IIb programme”).
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders
1/10/2022
Khondrion announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Mode of Action of the Mitochondrial Clinical-stage Drug Candidate Kh176: Two Birds, One Stone
4/26/2018
Khondrion announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases.
-
Khondrion Presents Phase II KHENERGY Trial Data
11/22/2017
Khondrion today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G multisystem mitochondrial MELAS and MIDD syndromes and mixed phenotypes.
-
New Patents Granted for Khondrion's Mitochondrial Disease Lead Compound KH176
11/8/2017
Khondrion announces today the grant of key patents in the United States of America, Europe and Hong Kong.